Screener
CRISPR Therapeutics CRSP Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Total assets | $2,725,820 | $2,265,243 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $13,647 | $11,138 |
| Accrued expenses | 74,932 | 89,407 |
| Deferred revenue, current | 15,344 | 15,771 |
| Accrued tax liabilities | 638 | 1,113 |
| Operating lease liabilities | 18,612 | 18,578 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's accounts payable?
- CRISPR Therapeutics (CRSP) reported accounts payable of $13.65M in Q1 2026.
- How has CRISPR Therapeutics's accounts payable changed year-over-year?
- CRISPR Therapeutics's accounts payable increased by 4.5% year-over-year, from $13.06M to $13.65M.
- What is the long-term trend for CRISPR Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's accounts payable has grown at a 4.1% compound annual growth rate (CAGR), from $9.09M to $11.14M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about CRISPR Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude